Lake Street Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating
Lake Street Remains a Buy on Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Checkpoint Therapeutics (CKPT), Mediwound (MDWD)
Lake Street Sticks to Its Buy Rating for Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics Analyst Ratings
Checkpoint Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Checkpoint Therapeutics, Maintains $34 Price Target
Buy Rating Affirmed for Checkpoint Therapeutics Despite FDA Setback: Solid Clinical Data Fuels Optimism for 2024 Market Entry
Checkpoint Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Milestone Pharmaceuticals (MIST), Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics Analyst Ratings
B. Riley Lowers Checkpoint Therapeutics' Price Target to $4 From $8, Keeps Buy Rating
Analyst Maintains Buy Rating for Checkpoint Therapeutics Amid FDA Setback, Citing Strong Approval Prospects and Market Potential
Checkpoint Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Checkpoint Therapeutics (CKPT)
Lake Street Remains a Buy on Checkpoint Therapeutics (CKPT)
Promising Clinical Data and Strong Financial Position: A Buy Rating for Checkpoint Therapeutics
B. Riley Lowers Checkpoint Therapeutics' Price Target to $8 From $15, Keeps Buy Rating
Lake Street Maintains Buy on Checkpoint Therapeutics, Lowers Price Target to $14
No Data